[1]谢 佳,张海英,李 娜,等.免疫炎症指数、血管表皮生长因子和胰岛素生长因子-1联合预测接受根治性放疗食管癌患者预后的价值[J].陕西医学杂志,2023,52(7):867-870，893.[doi:DOI:10.3969/j.issn.1000-7377.2023.07.021]
　XIE Jia,ZHANG Haiying,LI Na,et al.Value of S Ⅱ,VEGF and IGF-1 in predicting prognosis of patients with esophageal cancer receiving radical radiotherapy[J].,2023,52(7):867-870，893.[doi:DOI:10.3969/j.issn.1000-7377.2023.07.021]
点击复制

免疫炎症指数、血管表皮生长因子和胰岛素生长因子-1联合预测接受根治性放疗食管癌患者预后的价值
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
52
期数:
2023年7期
页码:
867-870，893
栏目:
临床研究
出版日期:
2023-07-05

文章信息/Info

Title:
Value of S Ⅱ,VEGF and IGF-1 in predicting prognosis of patients with esophageal cancer receiving radical radiotherapy
作者:
谢 佳; 张海英; 李 娜; 郑小琴; 王晓红
(遂宁市中心医院肿瘤中心二病区,四川 遂宁 629000)
Author(s):
XIE Jia; ZHANG Haiying; LI Na; ZHENG Xiaoqin; WANG Xiaohong
(The Second Ward of Cancer Center,Suining Central Hospital,Suining 629000,China)
关键词:
免疫炎症指数;  血管表皮生长因子;  胰岛素生长因子-1;  根治性放疗;  食管癌;  预后
Keywords:
Immune Inflammation Index;  Vascular epidermal growth factor;  Insulin growth factor-1;  Radical radiotherapy;  Esophageal cancer;  Prognosis
分类号:
R 735.1
DOI:
DOI:10.3969/j.issn.1000-7377.2023.07.021
文献标志码:
A
摘要:
目的:探讨免疫炎症指数(SⅡ)、血管表皮生长因子(VEGF)和胰岛素生长因子-1(IGF-1)联合预测接受根治性放疗的食管癌患者预后的价值。方法:选取接受根治性放疗的食管癌患者128例,随访患者术后1年生存情况,分为存活组(n=98)和病死组(n=30),比较两组临床资料、SⅡ、VEGF和IGF-1差异,分析SⅡ、VEGF和IGF-1与临床病理、预后的关系。结果:病死组患者年龄、病灶位于胸下段比例、病灶长度>6 cm比例、TNM分期Ⅲ比例、低分化比例、非同步化疗比例、处方剂量<61.2 Gy比例明显高于存活组患者(均P<0.05)。病死组患者SⅡ、VEGF和IGF-1水平明显高于存活组患者(均P<0.05)。TNM分期Ⅲ期、低分化患者SⅡ明显高于TNM分期Ⅰ-Ⅱ期、中高分化患者(均P<0.05); 病灶长度≥6 cm、TNM分期Ⅲ期、低分化患者VEGF水平明显高于病灶长度<6 cm、TNM分期Ⅰ-Ⅱ期、中高分化患者(均P<0.05); TNM分期Ⅲ期患者IGF-1水平明显高于TNM分期Ⅰ-Ⅱ期患者(均P<0.05)。Logistic回归分析显示:TNM分期、分化程度、SⅡ、VEGF和IGF-1是患者术后1年病死的影响因素(均P<0.05)。该方程预测患者术后1年病死的ROC曲线下面积为0.843,灵敏性和特异性分别为63.00%和91.00%。结论:SⅡ、VEGF和IGF-1水平与食管癌患者TNM分期、分化程度等临床病理有关,同时在预测食管癌患者根治性放疗预后方面有一定应用价值。
Abstract:
Objective:To investigate the value of Immunoinflammatory Index(SⅡ),vascular epidermal growth factor(VEGF)and insulin growth factor-1(IGF-1)in predicting prognosis of patients with esophageal cancer receiving radical radiotherapy.Methods:A total of 128 patients with esophageal cancer who received radical radiotherapy were selected and followed up 1 year after surgery.The patients were divided into survival group(98 cases)and death group(30 cases).The clinical data,SⅡ,VEGF and IGF-1 between the two groups were compared,and the relationship between SⅡ,VEGF,IGF-1 and clinicopathology and prognosis were analyzed.Results:The age,the proportion of lesion located in lower thoracic segment,the proportion of lesion length >6 cm,the proportion of TNM stage Ⅲ,the proportion of low differentiation,the proportion of non-synchronous chemotherapy and the proportion of prescription dose <61.2 Gy in death group were significantly higher than those in survival group(all P<0.05).The levels of SⅡ,VEGF and IGF-1 in death group were significantly higher than those in survival group(all P<0.05).The SⅡ of patients with TNM stage Ⅲ and low differentiation was significantly higher than that of patients with TNM stage Ⅰ-Ⅱ and medium-high differentiation(all P<0.05).The level of VEGF in patients with lesion length ≥6 cm,TNM stage Ⅲ and low differentiation was significantly higher than that in patients with lesion length <6 cm,TNM stage Ⅰ-Ⅱ and medium-high differentiation(all P<0.05).The level of IGF-1 in patients with TNM stage Ⅲ was significantly higher than that in patients with TNM stage Ⅰ-Ⅱ(P<0.05).Logistic regression analysis showed that TNM stage,differentiation degree,SⅡ,VEGF and IGF-1 were the influencing factors of death 1 year after surgery(all P<0.05).The area under ROC curve predicted by this equation was 0.843,and the sensitivity and specificity were 63.00% and 91.00%.Conclusion:The levels of SⅡ,VEGF and IGF-1 are related to clinical pathology such as TNM stage and differentiation degree,and have certain application value in predicting prognosis of patients after radical radiotherapy.

参考文献/References:

[1] Walls G,Walls G,White N,et al.Clinical outcomes after radical radiotherapy for lung cancer in patients with interstitial lung disease[J].Lung Cancer,2021,156(8):62-63.
[2] Li C,Wang X,Wang L,et al.Clinical practice and outcome of radiotherapy for advanced esophageal squamous cell carcinoma between 2002 and 2018 in China:The multi-center 3JECROG Survey[J].Acta Oncologica,2021,60(5):1-8.
[3] Gao R,Wang Z,Liu Q,et al.MicroRNA-105 plays an independent prognostic role in esophageal cancer and acts as an oncogene[J].Cancer Biomarkers:Section A of Disease Markers,2020,27(2):173-180.
[4] Zhang S,Tan Y,Cai X,et al.Preoperative weight loss is associated with poorer prognosis in operable esophageal cancer patients:A single-center retrospective analysis of a large cohort of Chinese patients[J].Journal of Cancer,2020,11(7):1994-1999.
[5] Rodriguez-Sanchez L,Macek P,Crehangec G,et al.Re:Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy(GETUG-AFU 17):A randomised,phase 3 trial[J].European urology,2020,21(10):1341-1352.
[6] Kanthabalan A,Arya M,Freeman A,et al.Intra-prostatic cancer recurrence following radical radiotherapy on transperineal template mapping biopsy:Implications for focal ablative salvage therapy[J].The Journal of Urology,2020,204(5):950-955.
[7] Sakanaka K,Fujii K,Mizowaki T.Adaptive radiotherapy in locally advanced esophageal cancer with atelectasis:A case report[J].BMC Cancer,2020,20(1):21-25.
[8] Mummudi N,Jiwnani S,Niyogi D,et al.Salvage radiotherapy for postoperative locoregional failure in esophageal cancer:A systematic review and meta-analysis[J].Diseases of the Esophagus,2022,35(3):e20.
[9] Fisher L.Retraction:Panax notoginseng saponins regulate VEGF to suppress esophageal squamous cell carcinoma progression via DVL3-mediated Wnt/β-catenin signaling[J].RSC Advances,2021,11(11):6258-6261.
[10] Feng C,Li P,Zhang F,et al.A meta-analysis of the association between the VEGF+936C>T gene polymorphism and digestive system cancer susceptibility[J].Genetic Testing and Molecular Biomarkers,2020,24(11):732-744.
[11] 曹志文,宋东奎,魏晓松,等.术前全身免疫炎症指数对非肌层浸润性膀胱癌患者肿瘤复发的预测价值[J].天津医药,2021,49(2):159-164.
[12] 俞正秋,赵滋苗,俞森权,等.全身免疫炎症指数预测合并实体恶性肿瘤ICU患者的临床结局一项倾向评分匹配研究[J].浙江医学,2021,43(8):836-840.
[13] 闫 可,魏菀怡,杨 洁,等.系统免疫炎症指数联合临床分期对食管癌患者预后的预测价值[J].中华放射医学与防护杂志,2022,42(1):25-31.
[14] 张广健,李益行,范 坤,等.肠功能恢复汤深部保留灌肠对食管癌术后患者肠功能恢复的疗效研究[J].陕西中医,2022,43(11):1560-1562.
[15] 赵 彦,沈文斌,李 娟,等.食管癌患者放疗前系统免疫炎症指数对长期生存的影响分析[J].中华放射医学与防护杂志,2022,42(3):198-203.
[16] 张春艳,刘明珠,侯 宁,等.系统免疫炎症指数对放化疗老年食管癌患者预后的预测作用[J].现代消化及介入诊疗,2021,26(3):314-318.
[17] 刘思凡,姜 娜,丁雪丽,等.放(或/和)化疗前NLR、SII、PNI对进展期食管癌患者预后的预测价值[J].胃肠病学和肝病学杂志,2021,30(12):1325-1330.
[18] 宋养荣,程 蒿,刘 佳,等.Ⅲ期食管癌新辅助化疗后行腔镜手术治疗临床研究[J].陕西医学杂志,2021,50(11):1358-1361.
[19] 柳 青,田 娜,王慧杰.食管癌患者血清中血管内皮生长因子和胰岛素样生长因子-1表达及其与临床病理特征的关系[J].实用癌症杂志,2022,37(1):54-56.
[20] 陈美玲,刘儒鹏,杨 军,等.食管癌患者血清中VEGF、Bcl-2表达及与放疗敏感性的相关性[J].实用癌症杂志,2022,37(7):1147-1149,1160.

备注/Memo

备注/Memo:
基金项目:四川省中医药管理局科学技术研究专项课题(2021MS302)
更新日期/Last Update: 2023-07-05